NSCLC: Safety Outcomes from HERTHENA-Lung01 : comparemela.co

Medical oncologists discuss the toxicity profile of patritumab deruxtecan and the safety outcomes from HERTHENA-Lung01 in non–small cell lung cancer.

Related Keywords

, Safety Outcomes , Non Small Cell Lung Cancer , Nsclc , Herthena Lung01 , Sadc , Antibody Drug Conjugate , Patritumab Deruxtecan , Adverse Events , Toxicity , Safety Profile , Treatment Emergent Adverse Events ,